Literature DB >> 12751038

Differential effects of priming with DNA vaccines encoding the hemagglutinin and/or fusion proteins on cytokine responses after measles virus challenge.

Fernando P Polack1, Scott J Hoffman, William J Moss, Diane E Griffin.   

Abstract

Measles is associated with a million deaths a year in developing countries because of secondary infections. Morbidity is particularly severe in young infants. Both measles-induced immune suppression and atypical measles have been associated with a type 2 cytokine bias of the immune response. The role of individual virus proteins in the induction of these cytokine responses is unknown and could be important for the development of new vaccines. We have used a rhesus macaque model and DNA vaccines to investigate cytokine responses to the individual measles virus (MV) protective antigens, hemagglutinin and fusion. The hemagglutinin protein primed for a type 2 cytokine response, with suppression of interleukin (IL)-12 and preferential production of IL-4 after MV challenge. The fusion protein primed for a type 1 response with preferential production of interferon-gamma. Responses were modulated when both proteins were used for priming. Therefore, the specific proteins included in a new measles vaccine will affect the type of cytokine response elicited.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12751038     DOI: 10.1086/375245

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.

Authors:  Man Ki Song; Christofer J Vindurampulle; Alejandra V E Capozzo; Jeffrey Ulmer; John M Polo; Marcela F Pasetti; Eileen M Barry; Myron M Levine
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins.

Authors:  Fernando P Polack; Shari L Lydy; Sok-Hyong Lee; Paul A Rota; William J Bellini; Robert J Adams; Harriet L Robinson; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

Review 3.  Emerging diseases: measles.

Authors:  Martin O Ota; William J Moss; Diane E Griffin
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

4.  A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles.

Authors:  Chien-Hsiung Pan; Catherine E Greer; Debra Hauer; Harold S Legg; Eun-Young Lee; M Jeff Bergen; Brandyn Lau; Robert J Adams; John M Polo; Diane E Griffin
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

5.  Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles.

Authors:  Chien-Hsiung Pan; Alexandra Valsamakis; Teresa Colella; Nitya Nair; Robert J Adams; Fernando P Polack; Catherine E Greer; Silvia Perri; John M Polo; Diane E Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-21       Impact factor: 11.205

6.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

7.  Vaccine-induced measles virus-specific T cells do not prevent infection or disease but facilitate subsequent clearance of viral RNA.

Authors:  Wen-Hsuan W Lin; Chien-Hsiung Pan; Robert J Adams; Beth L Laube; Diane E Griffin
Journal:  mBio       Date:  2014-04-15       Impact factor: 7.867

Review 8.  Measles studies in the macaque model.

Authors:  R L de Swart; R L DeSwart
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.